Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen's Plea To Stop Zarxio Launch Denied; Next Move?

This article was originally published in Scrip

Executive Summary

In a brief order on Sept. 2, a three-judge panel from the US Court of Appeals for the Federal Circuit denied Amgen's "emergency" motion for an injunction to stop Novartis unit Sandoz from launching its biosimilar Zarxio (filgrastim-sndz).



Related Companies